Drug class

Agents to Treat Resistant Gram Positive Organisms

"Agents to treat resistant Gram-positive organisms" is a descriptive clinical and formulary categorization rather than a single standardized pharmacological class. Read more about Agents to Treat Resistant Gram Positive Organisms

122 drugs in this class 74 manufacturers

Advertisement

Drugs in Agents to Treat Resistant Gram Positive Organisms

Showing 100–108 of 122 drugs

VANCOMYCIN HCL

VANCOMYCIN INTRAVENOUS · CLOSTRIDIOIDES DIFFICILE INFECTION ·+18
FRESENIUS KABI

VANCOMYCIN HCL

VANCOMYCIN INTRAVENOUS · CLOSTRIDIOIDES DIFFICILE INFECTION ·+18
GLENMARK PHARMA

LINEZOLID

OXAZOLIDINEDIONES · VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTION ·+11
GREENSTONE-MYLA

DAPTOMYCIN

AGENTS TO TREAT RESISTANT GRAM POSITIVE ORGANISMS · STAPHYLOCOCCUS AUREUS SEPTICEMIA ·+6
ENDO USA, INC.

DAPTOMYCIN

AGENTS TO TREAT RESISTANT GRAM POSITIVE ORGANISMS · STAPHYLOCOCCUS AUREUS SEPTICEMIA ·+6
Hikma Pharmaceuticals USA

VANCOMYCIN HCL

VANCOMYCIN INTRAVENOUS · CLOSTRIDIOIDES DIFFICILE INFECTION ·+18
MEDIMETRIKS PHA

DAPTOMYCIN

AGENTS TO TREAT RESISTANT GRAM POSITIVE ORGANISMS · STAPHYLOCOCCUS AUREUS SEPTICEMIA ·+6
Hikma Pharmaceuticals USA

DALBAVANCIN HCL

AGENTS TO TREAT RESISTANT GRAM POSITIVE ORGANISMS · COMPLICATED SKIN AND SKIN STRUCTURE STAPHYLOCOCCUS AUREUS INFECTION ·+6
TEVA PHARM
Filter & compare in the drug finder → Opens the drug finder with Agents to Treat Resistant Gram Positive Organisms preselected. Add indication or manufacturer filters there.

About Agents to Treat Resistant Gram Positive Organisms.

"Agents to treat resistant Gram-positive organisms" is a descriptive clinical and formulary categorization rather than a single standardized pharmacological class.

It encompasses structurally diverse antimicrobial classes—including glycopeptides (such as vancomycin), lipopeptides (such as daptomycin), oxazolidinones (such as linezolid), and lipoglycopeptides—that target bacterial cell wall synthesis, cell membrane integrity, or ribosomal protein synthesis.

These medications provide targeted bactericidal or bacteriostatic coverage against multidrug-resistant pathogens such as methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus* (VRE).

In clinical practice, they are indicated for serious, complicated infections, including acute bacterial skin and skin structure infections, bloodstream infections, endocarditis, osteomyelitis, and hospital-acquired pneumonia.